TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

February 2, 2027

Study Completion Date

February 2, 2027

Conditions

Epithelial OvarianFallopian TubePrimary Peritoneal Cancer

Interventions

DRUG

Paclitaxel/Bev (control)

Given by PO

DRUG

Paclitaxel/Bev + ZA (experimental)

Given by PO

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

Gateway for Cancer Research

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER